Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GeparNuevo: Durvalumab + Chemotherapy in TNBC
NCT02685059Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- Jun 2016
- Primary completion
- Mar 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in triple-negative breast cancer (TNBC), sponsored by GBG Forschungs. Started Jun 2016; status: completed.
02
Drugs
durvalumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02685059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02685059.